Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT06308978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06308978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
March 28, 2024
Completion date
September 30, 2042
Enrollment
244 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

antineutrophilic cytoplasmic antibody (anca)- associated vasculitis (aav), idiopathic inflammatory myositis (iim), lupus nephritis, systemic lupus erythematosus (sle), systemic sclerosis (ssc)